Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination is a chemotherapy regimen used primarily for treating early-stage breast cancer. Doxorubicin, an anthracycline antibiotic, damages DNA in cancer cells, preventing them from replicating. Cyclophosphamide, an alkylating agent, also damages DNA, particularly in the resting phase of the cell cycle, preventing cell division. Both drugs work synergistically to kill cancer cells.
- Brand names
- AC
- Other names
- Adriamycin + Cytoxan
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on doxorubicin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + cyclophosphamide.